ArticleMolecular psychiatry2026
Ceruloplasmin deficiency drives a fusiform-centric lipid-myelin pathology underlying a visual subtype in autism.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron dysregulation in the central nervous system: implications for autism spectrum disorder.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical visual processing (AVP) commonly occurs in autism spectrum disorder (ASD) and contributes to social impairments, yet its neurobiological basis remains poorly characterized. To investigate potential lipid and myelin mechanisms, this study integrated multimodal MRI, quantifying lipid (proton density fat fraction) and myelin content (synthetic MRI) of 74 nuclei or brain regions, with serum profiling of iron, lead, and ceruloplasmin in 288 children, including 90 ASD with atypical visual processing (ASD‑AVP), 89 ASD without atypical visual processing (ASD‑AVP), and 109 typically developing (TD). The ASD-AVP subgroup exhibited a distinct co-pathology of elevated lipid and myelin centered on the fusiform gyrus (FG), accompanied by a unique positive lipid-myelin correlation (left: r = 0.47, right: r = 0.41). Serum analyses revealed decreased iron and ceruloplasmin and increased lead in ASD-AVP, and mediation analysis indicated that ceruloplasmin deficiency influences FG myelination via lipid pathways (35%-55%). Crucially, BTBR AVP-like mice recapitulated this phenotype with disorganized hypermyelination, whereas nAVP-like mice showed hypomyelination. A combined FG lipid-myelin signature strongly distinguished ASD-AVP from TD (AUC = 0.93) and ASD-nAVP (AUC = 0.87). Preliminary longitudinal follow-up in a subset of patients revealed that improvement in serum ceruloplasmin was associated with a reduction in FG lipid content and stabilization of myelin, paralleling clinical improvement. These findings identify a ceruloplasmin-driven, FG-centric lipid-myelin co-pathology, representing a maladaptive "inflammatory pseudo-compensation" mechanism specific to a visual ASD subtype, and offer novel biomarkers for biological subtyping and targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.